Anja Wilkening
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anja Wilkening has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ulrich Palm
Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München
2 shared publications- Anna Katharina Kurzeck
Department of Psychiatry, Hospital of the University of Munich, 80336 Munich, Germany
1 shared publication Anna Kurzeck
Department of Psychiatry and Psychotherapy, University of Munich, Nussbaumstr. 7, 80336 Munich, Germany
1 shared publicationEsther Dechantsreiter
Department of Psychiatry and Psychotherapy, University of Munich, Nussbaumstr. 7, 80336 Munich, Germany
1 shared publication- Esther Dechantsreiter
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstr. 7, 80336 Munich, Germany
1 shared publication Frank Padberg
Department of Psychiatry and Psychotherapy, University of Munich, Nussbaumstr. 7, 80336 Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 19 July 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (7) , 947
Transcranial Direct Current Stimulation (tDCS) for Depression during Pregnancy: Results from an Open-Label Pilot Study
Introduction: Depression is the most common morbidity during pregnancy. Available first-line therapy options are limited and depressive disorders in pregnant women are often untreated, leading to negative effects on maternal and fetal health. Objectives: The aim of this open-label pilot study is to extend evidence on the use of transcranial direct current stimulation (tDCS) as a treatment of antenatal depression and to point out options for the use of tDCS in this population. Methods: Six drug-free female patients with major depressive disorder during pregnancy (later than 10th gestational week) were included in this pilot study. Patients were treated with twice-daily tDCS (2 mA, 30 min, anode: F3, cathode: F4) over ten days during inpatient stay (Phase 1) and with once-daily tDCS over 10 days during an optional outpatient stay (Phase 2). Clinical (HAMD-21, BDI) and neuropsychological ratings (Trail Making Test A/B) were performed at baseline, after two and four weeks as well as an obstetric examination. Results: Six right-handed females (23–43 years, 12–33. gestational week) completed Phase 1; four patients additionally joined in Phase 2. tDCS was well tolerated and no adverse effects occurred. Clinical ratings showed an improvement of mean baseline HAMD-21 from 22.50 ± 7.56 to 13.67 ± 3.93 after week 2, and to 8.75 ± 4.99 after week 4. The mean baseline BDI was 26.00 ± 13.90 and declined to 11.17 ± 5.46 after week 2, and to 9.25 ± 3.30 after week 4. Conclusions: Statistically significant changes in HAMD-21 and BDI were observed after Phase 1. One patient achieved remission in terms of HAMD in Phase 1. Although this small-scale study lacks sham control, it shows clinical improvement and absence of adverse events in this critical population.
- 19 July 2021
- Published by MDPI AG in Brain Sciences
- Vol. 11 (7) , 947
Open AccessTranscranial Direct Current Stimulation (tDCS) for Depression during Pregnancy: Results from an Open-Label Pilot Study
Introduction: Depression is the most common morbidity during pregnancy. Available first-line therapy options are limited and depressive disorders in pregnant women are often untreated, leading to negative effects on maternal and fetal health. Objectives: The aim of this open-label pilot study is to extend evidence on the use of transcranial direct current stimulation (tDCS) as a treatment of antenatal depression and to point out options for the use of tDCS in this population. Methods: Six drug-free female patients with major depressive disorder during pregnancy (later than 10th gestational week) were included in this pilot study. Patients were treated with twice-daily tDCS (2 mA, 30 min, anode: F3, cathode: F4) over ten days during inpatient stay (Phase 1) and with once-daily tDCS over 10 days during an optional outpatient stay (Phase 2). Clinical (HAMD-21, BDI) and neuropsychological ratings (Trail Making Test A/B) were performed at baseline, after two and four weeks as well as an obstetric examination. Results: Six right-handed females (23–43 years, 12–33. gestational week) completed Phase 1; four patients additionally joined in Phase 2. tDCS was well tolerated and no adverse effects occurred. Clinical ratings showed an improvement of mean baseline HAMD-21 from 22.50 ± 7.56 to 13.67 ± 3.93 after week 2, and to 8.75 ± 4.99 after week 4. The mean baseline BDI was 26.00 ± 13.90 and declined to 11.17 ± 5.46 after week 2, and to 9.25 ± 3.30 after week 4. Conclusions: Statistically significant changes in HAMD-21 and BDI were observed after Phase 1. One patient achieved remission in terms of HAMD in Phase 1. Although this small-scale study lacks sham control, it shows clinical improvement and absence of adverse events in this critical population.
- 3 July 2019
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 46 (05) , 287-289
Anstieg des Clozapinspiegels bei bronchopulmonalen Infekten: Häufiger als man denkt!
Zusammenfassung: Systemische Entzündungsreaktionen können über eine Hemmung der Cytochrom-P450-Proteine die Metabolisierung verschiedener Arzneimittel beeinflussen. Hier berichten wir über 2 Patienten mit schizophrener Psychose, die während eines pulmonalen Infekts stark erhöhte Clozapinspiegel, jedoch ohne klinisch sichtbare Nebenwirkungen, aufwiesen. Nach antibiotischer Behandlung und Reduktion der Clozapindosis normalisierte sich der Clozapinspiegel nach wenigen Tagen. Bei systemischen Infekten sollte an die Möglichkeit eines erhöhten Clozapinspiegels gedacht werden.
- 3 July 2019
- Published by Georg Thieme Verlag KG in Psychiatrische Praxis
- Vol. 46 (05) , 287-289
Anstieg des Clozapinspiegels bei bronchopulmonalen Infekten: Häufiger als man denkt!
Zusammenfassung: Systemische Entzündungsreaktionen können über eine Hemmung der Cytochrom-P450-Proteine die Metabolisierung verschiedener Arzneimittel beeinflussen. Hier berichten wir über 2 Patienten mit schizophrener Psychose, die während eines pulmonalen Infekts stark erhöhte Clozapinspiegel, jedoch ohne klinisch sichtbare Nebenwirkungen, aufwiesen. Nach antibiotischer Behandlung und Reduktion der Clozapindosis normalisierte sich der Clozapinspiegel nach wenigen Tagen. Bei systemischen Infekten sollte an die Möglichkeit eines erhöhten Clozapinspiegels gedacht werden.
- 9 June 2019
- Published by Elsevier in Psychiatry Research
- Vol. 279, 399-400
Transcranial alternating current stimulation for the treatment of major depression during pregnancy
- 9 June 2019
- Published by Elsevier in Psychiatry Research
- Vol. 279, 399-400
Transcranial alternating current stimulation for the treatment of major depression during pregnancy